(Q38372571)

2 September 2017

1 reference

title

Immune therapies in non-muscle invasive bladder cancer (English)

1 reference

2 September 2017

1 reference

Philip L Ho

1

1 reference

2 September 2017

Stephen B Williams

series ordinal

2

1 reference

2 September 2017

Ashish M Kamat

series ordinal

3

1 reference

2 September 2017

publication date

1 February 2015

1 reference

Current Treatment Options in Oncology

2 September 2017

published in

1 reference

2 September 2017

volume

16

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

5

1 reference

Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

The mechanism of action of BCG therapy for bladder cancer--a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Strategies for optimizing bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Invasive T1 bladder cancer: indications and rationale for radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Is radical cystectomy mandatory in every patient with variant histology of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Molecular confirmation of bacillus Calmette-Guérin as the cause of pulmonary infection following urinary tract instillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Treatment options for BCG failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Current and new strategies in immunotherapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Genome-wide association study identifies multiple loci associated with bladder cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Immunotherapeutic strategies for high-risk bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Aging and Innate Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0315-3

Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial

21 January 2018

1 reference

12 December 2020

Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP

1 reference

12 December 2020

What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?

1 reference

12 December 2020

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy

1 reference

12 December 2020

1 reference

12 December 2020

Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors

1 reference

12 December 2020

Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer

1 reference

12 December 2020

Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

1 reference

12 December 2020

Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study

1 reference

12 December 2020

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer

1 reference

12 December 2020

Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients

1 reference

12 December 2020

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine

1 reference

12 December 2020

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

1 reference

12 December 2020

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial

1 reference

12 December 2020

Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu�rin immunotherapy for carcinoma in situ of the bladder

1 reference

12 December 2020

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

1 reference

12 December 2020

Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer

1 reference

12 December 2020

Impact of a second transurethral resection on the staging of T1 bladder cancer

1 reference

12 December 2020

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 December 2020

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

1 reference

12 December 2020

Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy

1 reference

12 December 2020

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy.

1 reference

12 December 2020

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy

1 reference

12 December 2020

Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study

1 reference

12 December 2020

Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF

1 reference

12 December 2020

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

1 reference

12 December 2020

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci

1 reference

12 December 2020

The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer

1 reference

12 December 2020

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

The value of a second transurethral resection in evaluating patients with bladder tumors

1 reference

12 December 2020

IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.

1 reference

12 December 2020

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of mainte

1 reference

12 December 2020

Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone

1 reference

12 December 2020

Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent

1 reference

12 December 2020

Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer

1 reference

12 December 2020

Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone

1 reference

12 December 2020

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

1 reference

12 December 2020

Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.

1 reference

12 December 2020

Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer

1 reference

12 December 2020

Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

1 reference

12 December 2020

Radical Cystectomy for Carcinoma of the Bladder: 16 Years of Experience

1 reference

12 December 2020

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer

1 reference

12 December 2020

A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma

1 reference

12 December 2020

Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy

1 reference

12 December 2020

Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

12 December 2020

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy

1 reference

12 December 2020

Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation

1 reference

12 December 2020

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

1 reference

12 December 2020

Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study

1 reference

12 December 2020

Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders

1 reference

12 December 2020

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

1 reference

12 December 2020

Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed

1 reference

12 December 2020

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

1 reference

12 December 2020

Immunotherapy of guinea pig cancer with BCG.

1 reference

12 December 2020

Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy

1 reference

12 December 2020

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

1 reference

12 December 2020

Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Guérin Substrains

1 reference

12 December 2020

10.1007/S11864-014-0315-3

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1006162837

0 references

1 reference